PS
CNTA

Principal Securities’s Centessa Pharmaceuticals CNTA Stock Holding History

Principal Securities’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17
Closed -$412 – 1748
2025
Q3 		$412 Hold
17
– – ﹤0.01% 3571
2025
Q2 		$223 Buy
+17
New +$215 ﹤0.01% 3588

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Principal Securities's CNTA Position: Q4 2025 in Review

Principal Securities sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 17 shares — an estimated $412 sold.

Principal Securities first reported a position in CNTA in Q2 2025 and held it in 2 quarters. The position peaked at $412 in Q3 2025. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • Principal Securities reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 17 Centessa Pharmaceuticals shares in Q4 2025, an estimated $412.
  • Principal Securities first reported a position in Centessa Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Centessa Pharmaceuticals position peaked at $412 in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.